Compound class:
Synthetic organic
Comment: NMT5 is an aminoadamantane nitrate compound. It has been reported as a small molecule that reduces SARS-CoV-2 infection in vitro and in the Syrian hamster COVID-19 model [2]. NMT5 has a dual-mechanism of action. It simultaneously blocks SARS-CoV-2 ion channels (that are formed by the envelope protein, E, and are implicated in viral assembly, release, and pathogenesis) on the surface of the virion, and it chemically modifies the spike protein (S) to disrupt binding to ACE2 on host cells [2].
A patent from 2017 reveals that aminoadamantyl nitrate compounds have been proposed for the treatment of CNS disorders, by acting as selective uncompetitive antagonists of activated extrasynaptic NMDA receptors [1]. |
|
References |
1. Becker CK, Venkatraman MS, Zhang X, Larrick JW. (2019)
Aminoadamantyl nitrate compounds and their use to treat cns disorders. Patent number: WO2019104020A1. Assignee: Panorama Research, Inc.. Priority date: 22/11/2017. Publication date: 31/05/2019. |
2. Oh CK, Nakamura T, Beutler N, Zhang X, Piña-Crespo J, Talantova M, Ghatak S, Trudler D, Carnevale LN, McKercher SR et al.. (2023)
Targeted protein S-nitrosylation of ACE2 inhibits SARS-CoV-2 infection. Nat Chem Biol, 19 (3): 275-283. [PMID:36175661] |